Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.
about
P1343
Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statementBif-1 promotes tumor cell migration and metastasis via Cdc42 expression and activity.Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma PropertiesPreoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection.Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation.Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum.High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinomaCritical roles of p53 in epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells.14-3-3β Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells by Modulating Expression of MMP2 and MMP9 through PI3K/Akt/NF-κB PathwayTGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma.Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinomaUpregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma.Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal.14-3-3ζ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1α.Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma.RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription.Establishment of a Chinese bladder cancer cell line (T921) with high metastatic activity.Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis.Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.ICAM-1-related long non-coding RNA: promoter analysis and expression in human retinal endothelial cells.
P2860
Q28066038-2437AB6D-51BF-4FD6-8E1F-45761DE1CC21Q30008851-EE7F18DF-031E-46CD-841B-E3BD6EBF0A58Q33715750-265AF0FE-3C1C-4F34-AE79-805FD2C62C1FQ33912315-E1C32D17-68BE-4C6F-B251-1B02A0C5B8E0Q34355442-E673212D-B002-4840-976F-E64C7F2B9779Q34452728-00193B63-F15D-4D64-B2CE-A5775ECC57B5Q34786421-17C18102-13EF-44FE-BAFE-42047C7C2027Q34984096-1F802273-3AB0-4720-A8B7-79279665C19CQ35885159-6E7F2A13-DE59-4D53-AA77-41F2E4695A9FQ36237549-9F3FB6A2-09AD-453A-AD74-9618F2F78DC0Q36249781-664EE2ED-2BAE-48FC-BC0D-BBCA17A2BAC3Q36256407-F04D20CB-C741-464A-AAD7-0DC043D295A7Q36414399-0171B329-ADF1-463E-90F7-825CC24A9679Q36898047-A7B202DF-7E6F-4F39-9258-BBE3EA53FDE0Q37085900-D60DA51F-FFFA-4E8B-801B-76480EE1B128Q37596678-7E4DE4D0-A070-495E-925A-DC3B16A10192Q39007383-DE39E771-D9BD-4845-B9B5-C0BAE8C8C6A8Q39132853-2624E023-BF12-4C3F-B120-88835FCC875BQ39601416-950A25D4-49AA-44EB-B555-3A674AEC6BD2Q46457660-ED442193-7F61-4A1D-AE89-8F5D1F2012D9Q53187576-CD385461-83A7-4A5E-8193-19775A62BB45Q55028031-240A6D5B-1B50-47CE-8564-22F2C65B934A
P2860
Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@ast
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@en
type
label
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@ast
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@en
prefLabel
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@ast
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Characterisation of a novel ce ...... s of hepatocellular carcinoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605689
P407
P4510
P577
2010-05-11T00:00:00Z
P5875
P6179
1022825996